

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

23 Jun 2026

### Comparison of the effectiveness of methotrexate and actinomycin D in the treatment of patients with C-section ectopic pregnancy

#### Protocol summary

Registration timing: **prospective**

##### Study aim

The aim of this study is to investigate and compare the effect of methotrexate and actinomycin D on patients with cesarean scar ectopic pregnancy, due to less side effects, more accessibility and less costs in the treatment by Actinomycin-D as a chemotherapy agent that has side effects similar to methotrexate without central nervous system's side effects.

Last update: **2023-04-04, 1402/01/15**

Update count: **0**

##### Registration date

2023-04-04, 1402/01/15

##### Registrant information

###### Name

Mehrdad Zahmatkesh

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 23 3343 7844

###### Email address

mehrdadzahmatkesh@semums.ac.ir

##### Design

Two arm parallel group, double-blind, randomized, phase 3 clinical trial on 32 patients. Lottery method used for randomization.

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Settings and conduct

Eligible patients who referred to Hazrat Rasool Akram and Firozgar Hospital in Tehran were assigned to two groups, the first group received methotrexate and the second group Actinomycin D. Then, BHCG levels are recorded. If there is any complication, drop in hemoglobin or no reduction in BHCG, the intervention will be discontinued and resection of the mass will be performed by surgical intervention.

##### Expected recruitment start date

2023-05-05, 1402/02/15

##### Expected recruitment end date

2024-03-05, 1402/12/15

##### Participants/Inclusion and exclusion criteria

32 patients with C-section ectopic pregnancy will enrolled. Patients with vaginal bleeding and hemodynamic instability will be excluded.

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Intervention groups

First group will receive actinomycin D and the second methotrexate.

##### Trial completion date

empty

##### Main outcome variables

level of the blood chorionic gonadotropin hormone (BHCG)

##### Scientific title

Comparison of the effectiveness of methotrexate and actinomycin D in the treatment of patients with C-section ectopic pregnancy

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20151020024625N16**

Registration date: **2023-04-04, 1402/01/15**

##### Public title

Assessing the effectiveness of methotrexate and actinomycin D in the treatment of patients with C-section

ectopic pregnancy

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
Confirmed diagnosis of -section ectopic pregnancy  
**Exclusion criteria:**  
Gestational age more than 13 weeks at the time of diagnosis Heavy vaginal bleeding Hemodynamic changes

**Age**  
No age limit

**Gender**  
Female

**Phase**  
3

**Groups that have been masked**

- Care provider
- Outcome assessor
- Data analyser

**Sample size**  
Target sample size: **32**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
For randomization, at first stage, 32 spheres from one to 32 are considered and following that will randomly divided into two equal parts, including "1" (Intervention1) and group 2 (Intervention2), and then using a lottery container, the ball of each group taken out and the intended sequence will be recorded.

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**  
The blinding of the study is such that the care provider, outcome assessor and biostatistician do not know the content of the intervention. For administration, the drug is drawn by the researcher into the syringe and given to the clinical care provider for administration by mentioning the administration method. The outcome assessor records the outcome based on the patient's identity number according to the randomization table, and the data collected based on the number and mention of the first and second intervention is provided to the biostatistician for analysis.

**Placebo**  
Not used

**Assignment**  
Parallel

**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

**Ethics committee**  
**Name of ethics committee**

Ethics Committee, Iran University of Medical Sciences

**Street address**  
Hemmat Expressway

**City**  
Tehran

**Province**  
Tehran

**Postal code**  
۱۴۴۹۶۱۴۵۳۵

**Approval date**  
2022-08-06, 1401/05/15

**Ethics committee reference number**  
IR.IUMS.FMD.REC.1401.269

## Health conditions studied

### 1

#### Description of health condition studied

C-Section Ectopic Pregnancy

#### ICD-10 code

O00.9

#### ICD-10 code description

Ectopic pregnancy, unspecified

## Primary outcomes

### 1

#### Description

Level of the blood chorionic gonadotropin hormone (BHCG)

#### Timepoint

4, 7, 14 and 21 days after intervention

#### Method of measurement

Enzyme-Linked Immunesorbent Assay (ELIZA)

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Methotrexate is given as a single dose of 50 mg by intramuscular injection. This dose is repeated after 14 days if there is no therapeutic result.

#### Category

Treatment - Drugs

### 2

#### Description

Intervention group: Actinomycin D is given as a single dose of 0.5 mg by intravenous infusion. This dose is repeated after 14 days if there is no therapeutic result.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

**Name of recruitment center**  
Hazrat Rasool Akram hospital  
**Full name of responsible person**  
Soodabeh Jamali  
**Street address**  
Niyayesh  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1445613131  
**Phone**  
+98 21 6435 1000  
**Email**  
soodabehjamali@gmail.com

### 2

#### Recruitment center

**Name of recruitment center**  
Firoozgar hospital  
**Full name of responsible person**  
Soodabeh Jamali  
**Street address**  
Beh-Afarin Ave.  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
۱۵۹۳۷۴۷۸۱۱  
**Phone**  
+98 21 8214 1201  
**Email**  
soodabehjamali@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**  
Iran University of Medical Sciences  
**Full name of responsible person**  
Dr. Samideh Khoei  
**Street address**  
Hemmat Expressway  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
۱۴۴۹۶۱۴۵۳۵  
**Phone**  
+98 21 8860 2219  
**Email**

Schoolofmedicine@iums.ac.ir

**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Iran University of Medical Sciences  
**Proportion provided by this source**  
100  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

#### Contact

**Name of organization / entity**  
Iran University of Medical Sciences  
**Full name of responsible person**  
Dr. Setareh Nasiri Zeidi  
**Position**  
Assistant Professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Gynecology and Obstetrics  
**Street address**  
Niyayesh Ave.  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1445613131  
**Phone**  
+98 21 6435 1000  
**Email**  
setare\_n99@yahoo.com

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**  
Iran University of Medical Sciences  
**Full name of responsible person**  
Dr. Setareh Nasiri Zeidi  
**Position**  
Assistant Professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Gynecology and Obstetrics  
**Street address**  
Niyayesh Ave.

**City**

Tehran

**Province**

Tehran

**Postal code**

1445613131

**Phone**

+98 21 6435 1000

**Email**

setare\_n99@yahoo.com

**Person responsible for updating data****Contact****Name of organization / entity**

Semnan University of Medical Sciences

**Full name of responsible person**

Mehrdad Zahmatkesh

**Position**

Research Expert

**Latest degree**

Bachelor

**Other areas of specialty/work**

Epidemiology

**Street address**

Amin Avenue, Basidj Boulevard

**City**

Semnan

**Province**

Semnan

**Postal code**

3519899951

**Phone**

+98 23 3343 7838

**Fax****Email**

mehrdadzahmatkesh@semums.ac.ir

**Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

The data collection will be presented anonymously.

**When the data will become available and for how long**

After publishing of the results, the data will be delivered upon request and after verification.

**To whom data/document is available**

The data will be available only for academic researchers.

**Under which criteria data/document could be used**

In order to conduct similar studies.

**From where data/document is obtainable**

Direct request from the scientific responsible.

**What processes are involved for a request to access data/document**

After request and authentication, the data will be provided.

**Comments**